Ambrisentan
Back to searchMolecule Structure
Scientific Name
Ambrisentan
Description of the Drug
Ambrisentan is a selective type A endothelin receptor antagonist used to treat primary pulmonary arterial hypertension and pulmonary arterial hypertension based on diagnostic classifications.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06403
http://www.drugbank.ca/drugs/DB06403
Brand Name(s)
Letairis, Volibris
Company Owner(s)
Apotex Inc, Cipla Ltd, Sigmapharm Laboratories Llc, Sun Pharmaceutical Industries Ltd, Par Pharmaceutical Inc, Watson Laboratories Inc, Aurobindo Pharma Ltd, Gilead Sciences Inc, Mylan Pharmaceuticals Inc, Zydus Pharmaceuticals Usa Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Endothelin receptor, ET-A/ET-B | PROTEIN FAMILY | ANTAGONIST | CHEMBL2096678 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL3679 | |
| DrugBank | DB06403 | |
| PubChem: Thomson Pharma | 14779987 | |
| PubChem | 6918493 | |
| LINCS | LSM-45789 | |
| Nikkaji | J2.651.033C | |
| BindingDB | 50146710 | |
| EPA CompTox Dashboard | DTXSID4046282 | |
| DrugCentral | 4337 | |
| ChemicalBook | CB71011125 | |
| Guide to Pharmacology | 3951 | |
| rxnorm | LETAIRIS | AMBRISENTAN |
| PubChem: Drugs of the Future | 12015371 | |
| ChEBI | 135949 | |
| ZINC | ZINC000000538627 |
